Is NCT02610062 results overdue?

Yes — results are overdue. Primary completion was 2017-09-22; the FDAAA-801 reporting deadline (2018-09-22) passed 2829 days ago and no results are posted on ClinicalTrials.gov.

A Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Escalating Doses of AGS67E Given as Monotherapy in Subjects With Acute Myeloid Leukemia (AML)

NCT ID	NCT02610062 ↗
Sponsor	Astellas Pharma Global Development, Inc. (INDUSTRY)
Phase	PHASE1
Status	TERMINATED
Primary completion	2017-09-22 (ACTUAL)
Reporting deadline	2018-09-22 (completion + 365d)
Days overdue	2829
Results posted	No — check results tab ↗
FDA-regulated	drug: yes, device: no
Provenance	Flagged overdue on 2026-06-21 · SHA-256 `dc516bbfeb80f5db…` (hash-chained, tamper-evident)

Source of record: ClinicalTrials.gov NCT02610062. The reporting requirement is FDAAA 801 (Public Law 110-85 §801) and the Final Rule, 42 CFR Part 11.